Barcelona Institute for Global Health, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.
Bureau d'Étude et de Gestion de l'Information Statistique, Kinshasa, Democratic Republic of the Congo.
Lancet Glob Health. 2023 Apr;11(4):e566-e574. doi: 10.1016/S2214-109X(23)00051-7.
Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine is recommended at each antenatal care clinic visit in high-moderate transmission areas. However, its coverage remains unacceptably low in many countries. Community health workers can effectively deliver malaria preventive interventions. The aim of this study was to assess the effect of community delivery of IPTp (C-IPTp) on antenatal care and IPTp coverage.
A community-based IPTp administration approach was implemented in four sub-Saharan countries: the Democratic Republic of the Congo (DR Congo), Madagascar, Mozambique, and Nigeria. A quasi-experimental before and after evaluation by cluster sampling was designed where C-IPTp was implemented in selected country areas in different phases. Baseline (before C-IPTp implementation), midline, and endline household surveys were carried out to assess IPTp intake in pregnant women in 2018, 2019, and 2021. Eligible participants of the household survey were women of reproductive age (13-50 years old, depending on the country) that had a pregnancy that ended (any pregnancy regardless of pregnancy outcome) in the 6 months before the interview. For the first baseline surveys, the target population was women who had a pregnancy that ended in the 12 months before the interview. The primary outcome from the household surveys was the proportion of women who reported having received at least three doses of IPTp during pregnancy. The trial is registered at ClinicalTrials.gov, NCT03600844.
A total of 32 household surveys were conducted between March 15, and Oct 30, 2018, and data from 18 215 interviewed women were analysed. The coverage of at least three doses of IPTp (IPTp3+) increased after the first year of C-IPTp implementation in all project areas in DR Congo (from 22·5% [170/755] to 31·8% [507/1596]), Madagascar (from 17·7% [101/572] to 40·8% [573/1404]), and Nigeria (from 12·7% [130/1027] to 35·2% [423/1203]), with increases between 145·6% (Madagascar) and 506·6% (Nigeria). IPTp3+ coverage increased between baseline and endline in all districts, except for Murrupula (Mozambique) and ranged between 9·6% and 533·6%. This pattern was similar in DR Congo, Madagascar, and Nigeria, and in Mozambique, the increase was lower than the other countries. Antenatal care attendance did not change or increased lightly in all study countries.
C-IPTp was associated with an increase in IPTp uptake without reducing antenatal care attendance. The strategy might be considered for malaria control in pregnancy.
UNITAID [2017-13-TIPTOP].
在高-中度传播地区,建议在每次产前保健诊所就诊时使用磺胺多辛-乙胺嘧啶对孕妇进行间歇性预防治疗疟疾(IPTp)。然而,在许多国家,其覆盖率仍然低得令人无法接受。社区卫生工作者可以有效地提供疟疾预防干预措施。本研究旨在评估社区提供 IPTp(C-IPTp)对产前保健和 IPTp 覆盖率的影响。
在四个撒哈拉以南非洲国家实施了基于社区的 IPTp 管理方法:刚果民主共和国(DRC)、马达加斯加、莫桑比克和尼日利亚。采用了通过聚类抽样进行的准实验前后评估设计,其中 C-IPTp 在不同阶段在选定的国家地区实施。在 2018 年、2019 年和 2021 年进行了基线(在实施 C-IPTp 之前)、中期和终线家庭调查,以评估孕妇中 IPTp 的摄入量。家庭调查的合格参与者为育龄妇女(13-50 岁,取决于国家),在接受采访前的 6 个月内有妊娠结束(无论妊娠结局如何)。对于第一次基线调查,目标人群是在接受采访前 12 个月内妊娠结束的妇女。家庭调查的主要结果是报告至少接受过三次 IPTp 剂量的妇女比例。该试验在 ClinicalTrials.gov 注册,NCT03600844。
2018 年 3 月 15 日至 10 月 30 日期间共进行了 32 次家庭调查,分析了 18155 名接受采访的妇女的数据。在 DRC(从 22.5%[755/3396]增加到 31.8%[507/1596])、马达加斯加(从 17.7%[101/572]增加到 40.8%[573/1404])和尼日利亚(从 12.7%[130/1027]增加到 35.2%[423/1203])的所有项目地区,在实施 C-IPTp 的第一年之后,至少接受三次 IPTp 剂量(IPTp3+)的覆盖率有所增加,在马达加斯加和尼日利亚之间增加了 145.6%(马达加斯加)和 506.6%(尼日利亚)。在所有地区,除 Murrupula(莫桑比克)外,IPTp3+的覆盖率都有所增加,基线和终线之间的覆盖率在 9.6%至 533.6%之间。在刚果民主共和国、马达加斯加和尼日利亚以及莫桑比克,这种模式是相似的,而在莫桑比克,增幅低于其他国家。在所有研究国家,产前保健的出勤率没有变化或略有增加。
C-IPTp 与 IPTp 利用率的增加有关,而不会降低产前保健的出勤率。该策略可能被认为是怀孕期间疟疾控制的一种方法。
联合国艾滋病规划署[2017-13-TIPTOP]。